Skip to content

Insmed INSM Long-Term Debt

Long-Term Debt at other companies

ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$286M-6.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.99B+0.1%
Savara logo
SavaraSVRA
$30.07M+1.8%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$258.1M+0.6%

Other financials

Income statement

See full
Revenue$306.0M+230%
Gross profit$258.5M+261%
Operating income-$153.3M+38.2%
Net income-$163.6M+36.3%
EPS (diluted)-$0.76+46.5%

Balance sheet

See full
Cash & equivalents$582.2M+44.4%
Total debt$580.3M-49.2%
Total equity$704.9M+611%
Total assets$2.1B+15.2%

Cash flow

See full
Operating cash flow-$222.7M+15.0%
CapEx$3.5M-65.4%
Free cash flow-$226.2M+16.9%

Valuation

See full
Market cap$22.57B+13.2%
Enterprise value$22.57B+17.3%
P/S27.5×-22.6×

Profitability

See full
Gross margin81.8%+5.3pp
Operating margin-140.6%-43.9pp
Net margin-144.4%-45.3pp
FCF margin-112.5%-35.3pp

Returns & leverage

See full
Return on equity-294.5%
Debt / equity0.8×-10.7×
Current ratio4.5×-1.4×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insmed's long-term debt?
Insmed (INSM) reported long-term debt of $542.22M in Q1 2026.
How has Insmed's long-term debt changed year-over-year?
Insmed's long-term debt decreased by 50.9% year-over-year, from $1.11B to $542.22M.
What is the long-term trend for Insmed's long-term debt?
Over 5 years (2020 to 2025), Insmed's long-term debt has grown at a 8.7% compound annual growth rate (CAGR), from $356.32M to $540.96M.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.